Alembic Pharmaceuticals Financials
| APLLTD Stock | 1,042 4.00 0.39% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 6.2 B | 5.8 B |
|
|
Alembic | Select Account or Indicator |
Understanding current and past Alembic Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Alembic Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Alembic Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Alembic Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alembic Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Alembic Pharmaceuticals' management manipulating its earnings.
Alembic Pharmaceuticals Stock Summary
Alembic Pharmaceuticals competes with NRB Industrial, Shivalik Bimetal, Reliance Industrial, Sportking India, and Shyam Metalics. Alembic Pharmaceuticals is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE901L01018 |
| Business Address | Alembic Road, Vadodara, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | alembicpharmaceuticals.com |
| Phone | 91 26 5663 7000 |
You should never invest in Alembic Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Alembic Stock, because this is throwing your money away. Analyzing the key information contained in Alembic Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Alembic Pharmaceuticals Key Financial Ratios
Alembic Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Alembic Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Alembic Pharmaceuticals over time and compare it to other companies across industries.| Revenue | 61.12 B | ||||
| Gross Profit | 39.44 B | ||||
| EBITDA | 9.62 B | ||||
| Net Income | 6.16 B | ||||
| Total Asset | 64.46 B |
Alembic Pharmaceuticals Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 59.9B | 67.1B | 71.2B | 61.8B | 64.5B | 40.9B | |
| Other Current Liab | 418.9M | 2.7B | 3.0B | 855.4M | 2.7B | 1.8B | |
| Net Debt | 17.6B | 4.9B | 6.6B | 6.5B | 3.9B | 4.8B | |
| Cash | 718.4M | 980.6M | 610.9M | 754.8M | 1.2B | 1.1B | |
| Inventory | 11.9B | 14.9B | 16.1B | 14.8B | 16.4B | 9.2B | |
| Other Current Assets | 200K | 5.3B | 3.8B | 3.1B | 2.9B | 2.2B | |
| Total Liab | 28.0B | 16.4B | 18.8B | 18.1B | 16.3B | 14.3B | |
| Total Current Assets | 24.6B | 25.8B | 28.6B | 29.1B | 30.8B | 18.9B | |
| Retained Earnings | 15.4B | 24.2B | 25.5B | 35.7B | 40.3B | 42.3B | |
| Accounts Payable | 6.3B | 6.7B | 7.1B | 6.8B | 7.4B | 7.7B | |
| Short Term Debt | 8.7B | 3.1B | 6.4B | 6.5B | 4.5B | 3.9B | |
| Net Receivables | 12.0B | 3.5B | 8.1B | 10.5B | 10.2B | 7.0B | |
| Other Liab | 708M | 867.1M | 897.4M | 958.1M | 1.1B | 847.2M | |
| Net Tangible Assets | 24.5B | 29.2B | 48.0B | 50.8B | 58.5B | 61.4B | |
| Other Assets | (1.7M) | 1.1B | 1.1B | 1.2B | 1.4B | 1.5B | |
| Short Long Term Debt | 8.6B | 200K | 6.3B | 6.4B | 4.3B | 3.8B | |
| Long Term Debt Total | 8.9B | 2.7B | 721.4M | 692.3M | 623.1M | 591.9M | |
| Intangible Assets | 1.6B | 2.7B | 3.0B | 3.2B | 1.5B | 0.0 | |
| Net Invested Capital | 49.7B | 53.3B | 58.7B | 50.1B | 52.5B | 52.2B | |
| Net Working Capital | 7.1B | 13.0B | 10.6B | 12.7B | 16.2B | 11.2B |
Alembic Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 271.6M | 160.2M | 177.3M | 501.7M | 561.9M | 590.0M | |
| Total Revenue | 44.9B | 52.8B | 52.3B | 56.5B | 61.1B | 37.5B | |
| Gross Profit | 31.8B | 37.5B | 35.1B | 39.4B | 26.8B | 23.8B | |
| Operating Income | 11.1B | 13.0B | 5.9B | 4.4B | 5.8B | 6.2B | |
| Ebit | 10.7B | 13.8B | 6.4B | 4.4B | 6.9B | 6.5B | |
| Research Development | 426.4M | 253.8M | 505.9M | 290.7M | 4.7B | 5.0B | |
| Ebitda | 12.2B | 15.7B | 9.2B | 7.1B | 9.6B | 7.8B | |
| Cost Of Revenue | 13.1B | 15.2B | 17.2B | 17.1B | 34.3B | 36.1B | |
| Income Before Tax | 10.0B | 13.7B | 6.2B | 3.5B | 6.3B | 6.2B | |
| Net Income | 8.3B | 11.5B | 5.2B | 3.4B | 6.2B | 5.1B | |
| Income Tax Expense | 2.0B | 2.5B | 1.0B | 126.1M | 160M | 152M | |
| Minority Interest | (7.9M) | (289.6M) | (606.4M) | 247.5M | 222.8M | 233.9M | |
| Tax Provision | 2.0B | 2.5B | 1.0B | 126.1M | 160M | 152M | |
| Interest Income | 160.4M | 160.2M | 177.3M | 501.7M | 20.9M | 19.9M | |
| Net Interest Income | (254.3M) | (160.2M) | (177.3M) | (501.7M) | (561.9M) | (533.8M) |
Alembic Pharmaceuticals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Alembic Pharmaceuticals. It measures of how well Alembic is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Alembic Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Alembic had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Alembic Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (2.2B) | (3.0B) | (1.2B) | 1.3B | (1.7B) | (1.6B) | |
| Change In Cash | (1.3B) | 262.2M | (369.7M) | 143.9M | 447.3M | 469.7M | |
| Free Cash Flow | (2.9B) | 8.0B | 1.3B | 2.8B | 4.3B | 4.5B | |
| Depreciation | 1.6B | 1.8B | 2.9B | 2.8B | 2.7B | 2.9B | |
| Other Non Cash Items | (1.2B) | (3.3B) | 128M | 1.5B | 103.6M | 108.8M | |
| Capital Expenditures | 7.3B | 6.6B | 4.3B | 4.4B | 3.3B | 4.3B | |
| Net Income | 10.0B | 13.7B | 6.2B | 3.5B | 6.2B | 6.2B | |
| End Period Cash Flow | 718.4M | 980.6M | 610.9M | 754.8M | 1.2B | 1.1B | |
| Dividends Paid | 909.1M | 3.3B | 2.8B | 2.0B | 1.6B | 1.5B | |
| Net Borrowings | 6.2B | 2.2B | 5.9B | (12.6B) | (11.3B) | (10.8B) | |
| Change To Netincome | 12.2M | 562.6M | (1.4B) | 318.4M | 286.6M | 300.9M |
Alembic Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alembic Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Alembic Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alembic Pharmaceuticals competition to find correlations between indicators driving Alembic Pharmaceuticals's intrinsic value. More Info.Alembic Pharmaceuticals Limited is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.48 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Alembic Pharmaceuticals Limited is roughly 2.09 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Alembic Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Alembic Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Alembic Pharmaceuticals Systematic Risk
Alembic Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Alembic Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Alembic Pharmaceuticals correlated with the market. If Beta is less than 0 Alembic Pharmaceuticals generally moves in the opposite direction as compared to the market. If Alembic Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Alembic Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Alembic Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Alembic Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Alembic Pharmaceuticals Limited Total Assets Over Time
Alembic Pharmaceuticals November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Alembic Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Alembic Pharmaceuticals Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Alembic Pharmaceuticals Limited based on widely used predictive technical indicators. In general, we focus on analyzing Alembic Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Alembic Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 14.1 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 4.18 |
Complementary Tools for Alembic Stock analysis
When running Alembic Pharmaceuticals' price analysis, check to measure Alembic Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alembic Pharmaceuticals is operating at the current time. Most of Alembic Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alembic Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alembic Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alembic Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |